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In recipients of hematopoietic stem cell transplants (HSCTs), the mortality
associated with invasive fungal infections (IFIs) remains high, despite the
introduction of broad-spectrum antifungal agents over the past 2 decades.
Preventing exposure to fungal pathogens in this population is impossible;
therefore, clinicians have focused on prophylactic use of antifungal agents to
prevent IFIs in high-risk HSCT recipients. It is important to target antifungal
prophylaxis by type of HSCT (autologous or allogeneic), local epidemiology,
and risk factors for IFIs so that patients can receive the most appropriate agent
while balancing costs and the risks of toxicity, and minimizing the development
of resistance. To assist clinicians in weighing the pros and cons of currently
available antifungal agents when choosing a suitable prophylactic regimen, we
provide a review of several key prospective randomized trials that evaluated
various antifungal agents for primary prophylaxis in adult HSCT recipients. In
addition, we describe the epidemiology of and risk factors for IFIs in HSCT
recipients, the difficulties in diagnosing IFIs, antifungal agents used for
prophylaxis, and the goals of primary prophylaxis. Fluconazole remains the gold
standard for primary prophylaxis in autologous HSCT recipients. For allogeneic
HSCT recipients, the agent chosen for prophylaxis must be based on the patient’s
risk factors for IFIs. In low-risk patients, fluconazole is an appropriate agent to
use for primary prophylaxis immediately after transplantation. However, in
allogeneic HSCT recipients who develop complications, such as graft failure,
graft-versus-host disease, or cytomegalovirus infection, prophylaxis with a
mould-active agent should be used.
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Conclusion
Patients receiving hematopoietic stem cell
transplants (HSCTs) are at increased risk for
opportunistic infections with bacterial, viral, and
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in particular, fungal pathogens. The mortality
associated with invasive fungal infections (IFIs)
in HSCT recipients remains high, despite the
introduction of broad-spectrum antifungal agents
over the past 2 decades. Since preventing exposure
to fungal pathogens is impossible, clinicians have
focused on the prophylactic use of antifungal
agents to prevent IFIs in HSCT recipients at high
risk for these infections, such as patients who
experience prolonged neutropenia, recipients of
transplants from unmatched related donors or
matched unrelated donors, or patients with graft-
versus-host disease (GVHD). Administration of
prophylactic antifungal agents may expose
patients to unnecessary drugs, pose a risk of
toxicity, and lead to the emergence of resistant
pathogens; however, current limitations in the
diagnosis of fungal infections, and the high
mortality associated with them, warrant the use
of primary antifungal prophylaxis in high-risk
HSCT recipients.1
An ideal prophylactic antifungal agent would
have a broad spectrum of antifungal activity,
including Candida species and moulds, with a
high threshold for the development of resistance.
It would be available both intravenously and
orally, with 100% bioavailability with or without
food. In addition, it would neither require dosage
adjustments for patients with renal or hepatic
impairment nor plasma concentration monitoring,
and would have minimal adverse effects or drug
interactions. Unfortunately, such an ideal agent
does not yet exist, and clinicians must weigh the
pros and cons of currently available antifungal
agents to choose a suitable prophylactic regimen
for HSCT recipients.
The epidemiology of IFIs in this patient
population has changed over the past 2 decades.
More HSCT recipients are developing IFIs due to
non–Candida albicans yeasts or moulds, such as
Aspergillus species or Zygomycetes. The avail-
ability of newer agents, such as voriconazole,
posaconazole, and the echinocandins, that
demonstrate activity against non–C. albicans
yeasts, Aspergillus species, and (for posaconazole)
the Zygomycetes, has renewed the debate among
clinicians regarding the most appropriate
antifungal agent for primary prophylaxis in this
patient population.
For many years, fluconazole has been the
antifungal drug of choice for primary prophylaxis
in HSCT recipients. It provides excellent
antifungal activity against C. albicans, the most
common cause of IFIs, and has proved superior
in the prevention of invasive Candida infections
compared with topical agents (clotrimazole and
nystatin) and oral (nonabsorbable) amphotericin
B.2, 3 The introduction of itraconazole provided a
therapeutic option for patients at high risk for
IFIs due to Aspergillus species; however, its poor
oral bioavailability and drug interaction profile
made it a less desirable agent for prophylaxis in
HSCT recipients.
We performed a search of the PubMed database
by using the following key words: hematopoietic
stem cell transplant, peripheral blood stem cell
transplant, bone marrow transplant, antifungal
prophylaxis, fungal prophylaxis, and invasive
fungal infections. Our search was limited to
prospective, randomized clinical trials that included
adult HSCT recipients, and review articles, case
reports, and abstracts from 1966–August 2009
reported in the English language. Studies that
included less than 12% HSCT recipients or
included only topical agents (clotrimazole,
nystatin), oral amphotericin B, or ketoconazole
were excluded. In this review, we compare and
contrast the key prospective, randomized, clinical
trials examining antifungal agents for primary
prophylaxis in adult HSCT recipients, with an
emphasis on studies that have guided therapy to
the present day. We also review the epidemiology
of IFIs, obstacles in diagnosing IFIs, the risks and
benefits of antifungal prophylaxis, and key
factors to consider when choosing an antifungal
agent for primary prophylaxis in this patient
population.
Epidemiology of Invasive Fungal Infections in
Patients Undergoing Hematopoietic Stem Cell
Transplantation
Risk Factors
Hematopoietic stem cell transplantation is a
collective term used to describe bone marrow
transplantation, peripheral blood stem cell
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transplantation, or umbilical cord blood cell
transplantation. Recipients of HSCTs have
numerous risk factors that predispose them to
IFIs. The interplay among host risk factors,
environmental exposure, and the net state of
immunosuppression of the patient influences the
overall risk for IFIs. Host risk factors include
older age at the time of transplantation (because
of the natural decline in immune system function
with age), comorbidities such as diabetes
mellitus, colonization with fungi, iron overload,
splenectomy, and duration and severity of
neutropenia.4–7
Environmental exposures that may occur
during the pre- and posttransplantation period,
such as exposure to airborne moulds or water
sources and foods contaminated by or containing
fungi, are potential sources of IFIs. In addition,
most patients have compromised mucocutaneous
barriers because of conditioning (or preparative)
regimens—chemotherapy and/or radiation
therapy administered to prepare the HSCT
recipient to receive the donor’s bone marrow—
and central venous catheters that may facilitate
the translocation of Candida species from the
skin or gastrointestinal tract. Furthermore,
HSCT recipients often receive broad-spectrum
antibiotics that can alter the normal gastrointestinal
flora, creating environmental conditions that are
optimal for the growth of fungi.4, 6
The net state of immunosuppression of a
patient is influenced by the type of preparative
regimen received before transplantation, the
agents used for the prevention and treatment of
GVHD, or infection with immunomodulating
viruses. Agents used for conditioning or to
prevent or treat GVHD, such as fludarabine,
antithymocyte globulin, alemtuzumab, rituximab,
calcineurin inhibitors, infliximab, basilizimab,
daclizumab, etanercept, sirolimus, or cortico-
steroids, may inhibit T- and/or B-lymphocyte
function or affect tumor necrosis factor- or
interleukin-2. All of these agents contribute to
impaired humoral- and/or cell-mediated
immunity and are known to, or in theory,
increase the risk for IFIs. Finally, coinfection
with cytomegalovirus or Epstein Barr virus
increases the risk for IFIs, as these viruses
suppress T- and B-lymphocyte function. In
particular, infection with cytomegalovirus or
respiratory virus infections (respiratory syncytial
virus and parainfluenza or influenza virus)
increases the risk of late-onset invasive
aspergillosis.4-8
The type of transplant a patient receives and
the source of the cells also influence the risk for
IFIs. In general, autologous transplant recipients
have a lower risk for IFIs than do allogeneic
transplant recipients. For both autologous and
allogeneic HSCT recipients, the risk for IFIs
increases in patients who experience prolonged
neutropenia, receive ex vivo CD34 selection, or
develop cytomegalovirus.6 Allogeneic transplant
recipients have additional risk factors that
increase susceptibility to IFIs compared with
autologous transplant recipients. To start,
allogeneic transplant recipients have a slower
reconstitution of cell-mediated immunity,
especially when GVHD is present, after trans-
plantation.6, 8–10 Further, patients who receive T-
cell–depleted transplants are unable to develop
antigen-specific T-cell responses after transplan-
tation, which hinders the immune response to
fungi.11 Moreover, recipients of human leukocyte
antigen (HLA) unmatched related donor or
matched unrelated donor cells are at higher risk
for IFIs.6, 8 Genetic polymorphisms in genes
encoding interleukin-10, tumor necrosis factor
receptor type 2, and toll-like receptors 1, 4, and 6
are also associated with a higher risk of invasive
aspergillosis.8 Finally, the source of hematopoietic
cells influences the risk of IFIs in allogeneic
transplants: HLA-matched related peripheral
stem cell transplant recipients have a lower risk
for IFIs than do patients receiving matched related
bone marrow or cord blood cell transplants.6
Causative Pathogens
Classically, the pathogens responsible for IFIs
in HSCT recipients have been primarily Candida
and Aspergillus species. In a retrospective study
of HLA-identical sibling allogeneic HSCT
recipients, the frequency of IFIs from 1996–2000
was 14%, despite most patients having received
antifungal prophylaxis with fluconazole,
itraconazole, or amphotericin B. Invasive
candidiasis occurred in 3% of patients, whereas
non-Candida IFIs, primarily Aspergillus
infections, occurred in 12% of patients.10 In a
recent large multicenter study, the cumulative
incidence of proven or probable aspergillosis 12
months after autologous HSCT was 0.5%. The
cumulative incidence of proven or probable
aspergillosis at 12 months after HSCT was greater
in allogeneic HSCT recipients: 2.3% for HLA-
matched related donors, 3.2% for HLA-
mismatched related donors, and 3.9% for
transplants from unrelated donors. Earlier
studies are difficult to compare with newer
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studies due to differences in definitions for
invasive aspergillosis.7 More than half of the IFIs
reported in this study were caused by Aspergillus
fumigatus.12
When assessing an HSCT recipient for anti-
fungal prophylaxis, it is important to consider
the time frame since transplantation, as this will
impact the likelihood of each fungal pathogen
(Figure 1).13 Engraftment, at which time the
absolute neutrophil count (ANC) has increased
to greater than 500–1000 cells/mm3, usually
occurs on or before approximately day 30 after
transplantation, and may be influenced by the
use of growth factors. During the preengraftment
period, patients are neutropenic and may have
breaks in their mucocutaneous barrier, placing
them at high risk for infections due to Candida
species. A smaller, yet significant number of
invasive mould infections (IMIs), such as
aspergillosis, are observed in this period,
particularly in patients with delayed neutrophil
engraftment and those administered T-cell–
depleted or CD34-selected stem cell products.6
Candida infections continue to occur in the post-
engraftment period; however, in the postengraft-
ment and late-phase periods, impaired cell-
mediated immunity, infection with immuno-
modulating viruses, GVHD, and immunosup-
pressive agents used to prevent or treat GVHD
increase a patient’s susceptibility to IMIs due to
Aspergillus species as well as other moulds such
as Zygomycetes.6, 7
Pathogenesis of Candida Infections
Candida infections in HSCT recipients usually
occur within the first 100 days after transplan-
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Figure 1. Phases of opportunistic infections among recipients of an allogeneic hematopoietic stem cell transplant (HSCT).
aMay occur without standard prophylaxis. bOccurs primarily among persons who are seropositive before transplantation.
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tation, spanning the pre- and postengraftment
period, mainly as a result of neutropenia and
disrupted macrophage function.13 Recently,
investigators demonstrated that patients bearing
the DECTIN-1 Y238X polymorphism had
increased oral and gastrointestinal colonization
with Candida species, rendering them at increased
risk for fungal infections.14 Translocation of
Candida species across the gastrointestinal
mucosa that has been damaged by chemotherapy
or GVHD, or from the skin through central
venous catheters, are the most common pathogenic
routes of infection. The risk of Candida infections
decreases after day 100, as patients have restored
neutrophil and macrophage function and catheters
have usually been removed by this time.15
Pathogenesis of Aspergillus and Other Mould
Infections
Mould infections in HSCT recipients are
primarily caused by environmental exposure.
Preventive measures include high-efficiency
particulate air filters, restriction on the use of
showers, and avoidance of foods containing
moulds during the high-risk period. Although
environmental protection from fungal pathogens is
a key component for preventing IFIs, it is impos-
sible to maintain patients in sterile environments
throughout the entire recovery period after
transplantation, justifying the use of antifungal
agents as prophylaxis. There is a bimodal pattern
in the frequency of IMIs in HSCT recipients, with
a lower rate in the preengraftment period, due to
neutropenia, and then a higher rate in the
postengraftment and late-phase periods, due to
impaired cell-mediated immunity and GVHD and
its associated therapy.6, 8, 15
Changing Epidemiology
The epidemiology of IFIs in HSCT recipients
continues to evolve. Although there has been a
decrease in IFIs caused by C. albicans as a result of
fluconazole prophylaxis, patients may now be at
an increased risk for IFIs due to non–C. albicans
Candida species. The IFIs due to non–C. albicans
Candida species, such as Candida glabrata,
Candida krusei, Candida tropicalis, Candida
parapsilosis, and Candida lusitaniae, and Candida
isolates resistant to azoles have been reported.16, 17
Furthermore, IFIs caused by species of Aspergillus
other than fumigatus have also been described.18,
19 The IFIs caused by such pathogens have been
described only in case reports thus far, making it
difficult to obtain a sense of whether there has
been an increase in incidence and whether this is
directly linked to the widespread use of newer
antifungals such as voriconazole or
echinocandins as prophylaxis.
In addition to shifts in the species of Candida
and Aspergillus causing IFIs, an increased
incidence of IFIs caused by Zygomycetes,
including species of Absidia, Mucor, Rhizomucor,
and Rhizopus, has been noted. Although these
pathogens were noted to increase after the
introduction of fluconazole for prophylaxis, some
investigators have postulated that these more
recent increases are attributable to the selective
pressure of more broad-spectrum antifungals such
as voriconazole and the echinocandins, which
cover Aspergillus species but lack coverage of
Zygomycetes, and/or the use of more potent
immunosuppressive regimens.20, 21 Several case
reports and an observational case-control study
of allogeneic HSCT recipients have documented
the development of zygomycosis in patients who
received voriconazole or caspofungin prophylaxis
or therapy.17–24 They noted that, in general,
before use of these newer antifungal agents,
zygomycoses had been noted only rarely in HSCT
recipients. However, whether a true increase in
zygomycoses exists is uncertain, and if present,
whether the increase is attributable to the increased
use of voriconazole or echinocandins is unclear.
The use of more potent immunosuppressive
agents, changes in the methods and types of
transplantation, and other comorbidities may
also contribute to increasing a patient’s risk for
these infections.
Mortality
Mortality due to IFIs in HSCT recipients is
difficult to quantify, as the definition of an IFI
varies among studies, and there are additional
confounding factors, including the type of trans-
plantation (autologous or allogeneic, peripheral
stem cells or bone marrow cells). Despite
administration of antifungal prophylaxis to most
HSCT recipients, crude and attributable mortality
due to Candida bloodstream infections is 32%
and 42%, respectively; mortality increases to
approximately 88% with organ or deep tissue
(e.g., liver, kidney) involvement.5, 25 For HSCT
recipients with a diagnosis of invasive aspergillosis,
the 3-month post-HSCT mortality rate is 53.8%
for autologous transplant recipients but approaches
90% for allogeneic HSCT recipients.12, 26 However,
the overall 1-year survival rate is only about 20%
for autologous and allogeneic HSCT recipients
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with proven or probable invasive mould
infections.27
Diagnosis of Invasive Fungal Infections
The diagnosis of IFIs in HSCT recipients is
challenging; in addition, there are inconsistencies
in the criteria defining an IFI. The Invasive
Fungal Infections Cooperative Group from
Europe and the Mycoses Study Group in the
United States have developed (and recently
updated) definitions for clinical researchers to
use when investigating IFIs in patients with
cancer and in HSCT recipients.28 A proven IFI is
defined as a positive fungal culture or histologic
demonstration of fungal or hyphal elements in a
biopsy from a sterile site with systemic signs and
symptoms of infection. Probable and possible
IFIs are further defined on the basis of specific
host factors, clinical manifestations of fungal
infection, and mycologic findings and are
discussed further elsewhere.29 Although these
definitions are used to standardize enrollment of
patients in clinical trials and are not meant to
guide clinical practice, they further underscore
the difficulties in diagnosing IFIs in immuno-
compromised patients.
Recipients of a HSCT may have blunted or
nonspecific signs and symptoms of infection
because of impaired inflammatory responses.11
Generally, patients are febrile, and dyspnea and
chest pain are common symptoms as the lungs
are the most common organ affected in IMIs.
However, disseminated infection is common,
particularly in recipients of allogeneic HSCTs,
and involvement of the central nervous system is
observed in a significant number of patients.7
Distinguishing between colonization and
infection is challenging. Cultures positive for
species of Candida or Aspergillus from sterile sites
are indicative of infection. However, the chal-
lenge occurs when these pathogens are cultured
from nonsterile sites. For example, isolation of
Aspergillus species from bronchial washings,
sputum, or nasal secretions may not always
indicate an invasive pulmonary or sinus
Aspergillus infection.11 Urinary candidiasis,
although rarely the source of subsequent
dissemination, may be a marker of acute
hematogenous dissemination in neutropenic
patients. A definitive diagnosis of invasive
pulmonary aspergillosis can be made by
obtaining a biopsy of lung tissue; however,
thrombocytopenia often limits a clinician’s ability
to perform this procedure in HSCT recipients.
Generally, the diagnosis is determined with the
use of high-resolution computed tomography, in
which invasive pulmonary aspergillosis will
manifest early on as a nodular opacity with
surrounding attenuation, or “halo sign.” In late
invasive aspergillosis, nodular lesions, diffuse
pulmonary infiltrates, consolidation, or ground-
glass opacities can be observed.7, 11 These signs
are not specific to invasive pulmonary aspergillosis,
however, as bacteria and other fungal infections
may produce similar findings.
New laboratory methods for detecting IFIs are
being considered since other diagnostic methods
may not always be definitive. A test that allows
for early differentiation of IFIs due to Aspergillus
species versus Zygomycetes and other moulds
would be helpful to clinicians in the earlier
initiation of appropriate antifungal therapy.
Testing based on polymerase chain reaction is
being performed in some centers and appears
promising; however, no U.S. Food and Drug
Administration (FDA)–approved method is
commercially available.
The galactomannan test is an enzyme-linked
immunosorbent assay that detects galactomannan,
an antigen released from Aspergillus hyphae on
invasion of host tissue. The utility of this assay
has been assessed in the clinical setting by
sampling serum, bronchoalveolar lavage fluid,
cerebrospinal fluid, and pleural fluid; however,
the currently approved test is performed on
serum. The test has a sensitivity ranging from
30–100% and a specificity of approximately 85%;
however, the sensitivity of the assay is decreased
in patients receiving mould-active drugs on the
day of sampling.11 False-positive results can
occur, particularly in patients receiving
cyclophosphamide or piperacillin-tazobactam,30, 31
and differences exist in the cutoff values for a
positive result between the United States and
Europe. False-negative results can occur during
the concomitant use of antifungals, presumably
because the level of galactomannan is related to
the fungal burden.11 In addition, it is important
to note that the utility of galactomannan testing
in the setting of prophylaxis has not been
defined.
1,3-,D-Glucan is a component of fungal cell
walls that can be detected colorimetrically in
clinical samples, including blood and broncho-
alveolar lavage specimens. However, the current
FDA-approved test is performed only on serum.
The 1,3-,D-glucan test can be used to detect
most fungi, except for Zygomycetes and
cryptococci, with a sensitivity of 55–100% and a
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specificity of 52–100%. However, the test can
produce false-positive results in patients under-
going hemodialysis with cellulose membranes, as
well as in other cases for unclear reasons.11 One
way to effectively use the 1,3-,D-glucan or
galactomannan assays may be to serially screen
patients who are at high risk for IFIs and/or use
them to monitor response to therapy as, for
instance, galactomannan results decline in
patients responding to treatment.7, 11
Goals of Antifungal Prophylaxis
Before delving into a discussion about prophy-
laxis, it is important to distinguish between the
different approaches to the management of IFIs
in HSCT recipients. Primary prophylaxis
provides patients (who have never had an IFI in
the past) at high risk for IFIs with an antifungal
regimen selected specifically to prevent IFIs.
Secondary prophylaxis, which is not discussed as
it is beyond the scope of this article, refers to
providing a patient who has a history of an IFI
with an antifungal agent to prevent a recurrence
of the IFI during subsequent episodes of
neutropenia or immunosuppression. By contrast,
preemptive therapy is triggered on detection of
an early indicator suggestive of an IFI, such as
fungal antigens or metabolites, colonization of
the respiratory tract with Aspergillus species, or
the appearance of a halo sign on a high-resolution
computed tomography scan. Empiric therapy
refers to the addition of an antifungal agent if a
patient has had a fever that is unresponsive to
broad-spectrum antibiotics for 72–96 hours.
Finally, treatment is the term applied when an
antifungal agent is used for a documented IFI.
The goal of primary antifungal prophylaxis in
HSCT recipients is to prevent morbidity and
mortality from IFIs, as early diagnosis is difficult
and treatment of IFIs is challenging. Recovery of
neutropenia, remission of the hematologic
malignancy, and prolonged antifungal therapy are
necessary for cure. A secondary goal is to reduce
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Table 1. Comparison of Antifungal Agents32, 33
Characteristic Amphotericin B Fluconazole Itraconazole OS Voriconazole Posaconazole
Antifungal activity
Candida sp Yesa Yesb Yes Yes Yes
Aspergillus sp Yesc No Yes Yes Yes
Zygomycetes Yes No No No Yes
Cryptococcus Yes Yes Yes Yes Yes
neoformans
Formulation i.v. i.v., p.o. p.o.d i.v., p.o. p.o.
Oral bioavailability NA > 90% ~55% ~96% NA
Give oral formulation NA With or without Without food Without food With fatty
with or without food food food
Dosage adjustment
Renal impairment Yes Yes Noe Not for p.o.e No
Hepatic impairment No No No Yes No
Drug interactions Minor Moderate Major Major Major
CYP enzymes No 3A4, 1A2, 2C8/9 3A4 3A4, 2C9, 2C19 3A4
Plasma concentration No No Yes Yes Unclear
monitoring suggested
Cost/day (AWP) < $50 to > $100 < $50 < $50 $50–100 $50–100
Adverse effects
Renal Yes No Noe With i.v. onlye No
AST or ALT level
elevation No Yes Yes Yes Yes
Abdominalf No Yes Yes Yes Yes
Infusion-related Yes No No No No
Visual No No No Yes No
Rash No Yes Yes Yes Yes
OS = oral solution; NA = not applicable; CYP = cytochrome P450; AWP = average wholesale price; AST = aspartate aminotransferase; ALT =
alanine aminotransferase.
aAmphotericin B has no in vitro activity against Candida lusitaniae.
bFluconazole has no in vitro activity against Candida krusei and has dose-dependent activity against Candida glabrata.
cExcept Aspergillus terreus.
dIntravenous itraconazole was discontinued in the United States in 2008.
eIntravenous itraconazole is not recommended in patients with creatinine clearance < 30 ml/min; i.v. voriconazole is not recommended in
patients with creatinine clearance < 50 ml/min.
fAbdominal adverse effects include anorexia, nausea, vomiting, diarrhea, or abdominal pain.
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fungal colonization. However, the risks of
prophylaxis must also be weighed in deciding
whether patients should receive prophylaxis, and
if so, the specific antifungal agent and duration of
antifungal therapy. Toxicity due to the antifungal
agent, promotion of resistance, selection of fungi
not covered by the antifungal resulting in a shift
from one fungal species to another, increasing the
potential for drug interactions, and cost are all
factors that need to be considered before
initiation of antifungal prophylaxis. Despite the
risks involved with providing HSCT recipients
with prophylaxis, the benefit of preventing
morbidity and mortality due to IFIs warrants the
use of primary antifungal prophylaxis in the
highest risk patients. By targeting prophylaxis
specifically to high-risk patients, taking into
account the basal frequency of IFIs in the
surrounding environment, host risk factors, type
of HSCT received, specific therapeutic interven-
tions received, and transplant complications,
antifungal prophylaxis can be used appropriately
without posing unnecessary risks.
Antifungal Agents
In addition to the results of clinical trials, when
considering an antifungal agent for a specific
patient, it is important to consider its spectrum
of activity against fungal pathogens, mechanism
of action, dosage adjustments for renal or hepatic
impairment, adverse-effect profile, drug
interaction potential, dosage formulation, oral
bioavailability with or without food, the need for
plasma concentration monitoring, and cost
(Table 1).32, 33 A more detailed description of the
pharmacology of antifungal agents is published
elsewhere.32
Amphotericin B formulations, the triazoles,
and the echinocandins all have activity against
most Candida species. However, a few exceptions
should be noted. Fluconazole has no activity
against C. krusei or Aspergillus species and
generally displays dose-dependent activity
against C. glabrata. Despite initial in vitro
sensitivity of C. lusitaniae to amphotericin B, its
clinical use is often associated with failure
because of the rapid development of acquired or
inducible resistance. Whereas amphotericin B,
itraconazole, voriconazole, posaconazole, and the
echinocandins are active against Aspergillus
species, only amphotericin B and posaconazole
display activity against Zygomycetes.
Amphotericin B and the echinocandins are
available only in intravenous formulations,
whereas posaconazole and itraconazole are
available only in oral formulations. The
availability of both oral and intravenous
formulations of fluconazole and voriconazole has
made these agents easier to use in HSCT recipients,
as the patient can be switched between dosage
forms as needed. From a therapeutic standpoint,
oral formulations of antifungal agents can reduce
gastrointestinal flora, decreasing the possibility of
translocation of Candida species (but not
moulds) into the bloodstream. However, a
counterargument is that altering the normal
gastrointestinal flora may create conditions that
are conducive to the growth of other fungi (e.g.,
non–C. albicans yeasts) or bacteria. The use of
intravenous dosage forms increases cost and the
risk of catheter-related line infections, but they
may not have as great an impact on the gastro-
intestinal flora. Although the bioavailability of
the oral formulations of fluconazole and
voriconazole approach 100%, itraconazole oral
solution is only about 55% bioavailable. Finally,
the bioavailability and tolerability of these agents
as well as the need for administration with meals
should be taken into account. Posaconazole must
be taken with a fatty meal to ensure absorption of
the drug. Many patients have difficulty tolerating
oral itraconazole solution because it needs to be
administered on an empty stomach, and it causes
1313
Table 1. (continued)
Caspofungin Micafungin Anidulafungin
Yes Yes Yes
Yes Yes Yes
No No No
No No No
i.v. i.v. i.v.
NA NA NA
NA NA NA
No No No
Yes No No
Minor Minor Minor
No No No
No No No
$50–100 $50–100 $50–100
No No No
Yes Yes Yes
No No No
Yes Yes Yes
No No No
Yes Yes Yes
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a lot of abdominal discomfort. Other patients
may not be able to tolerate the visual disturbances
caused by voriconazole.32
As HSCT recipients generally receive a large
number of drugs after transplantation, it is
necessary to evaluate the drug interaction
potential of antifungal agents that are used for
prophylaxis. The azole antifungal agents alter
plasma concentrations of a number of other
drugs (in particular, many immunosuppressive
agents) that undergo metabolism by cytochrome
P450 (CYP) enzymes. A more detailed descrip-
tion of these interactions is available elsewhere.33
By contrast, amphotericin B and the echinocandins
have few drug interactions.32
Plasma concentration monitoring may be
necessary when using an antifungal for prophylaxis,
to ensure efficacy, absorption, and safety. It is not
necessary to monitor concentrations of amphotericin
B or the echinocandins; however, monitoring
serum concentrations (after 7 days of adminis-
tration or after dosage changes) is recommended
for itraconazole, voriconazole, and possibly
posaconazole.32, 34, 35
As the bioavailability of itraconazole oral
solution is suboptimal, plasma concentration
monitoring (combining the concentration of
itraconazole plus the active metabolite hydroxy-
itraconazole) is recommended to ensure that
adequate absorption is achieved. The target
range for itraconazole trough concentrations is at
least 0.5–1 µg/ml.32, 34, 36, 37
Monitoring of plasma voriconazole
concentrations is recommended because of its
variable metabolism, to ensure adequate concen-
trations for prophylactic efficacy and prevent
adverse events with supratherapeutic concentrations.
Voriconazole concentrations of 2–6 µg/ml have
been recommended; two studies have correlated
plasma concentrations greater than 2.05 µg/ml
with greater efficacy, and concentrations less than
0.25 µg/ml with failure to respond in the treatment
of invasive aspergillosis.35, 38 Higher plasma
concentrations have been correlated with toxicity:
trough concentrations greater than 5.5 µg/ml
have been correlated with neurologic toxicity.
However, whether these concentrations are
applicable in the prophylaxis of fungal infections
is not known.32, 35, 38–43
Although it is unclear whether posaconazole
requires plasma concentration monitoring, it is
likely that monitoring will be recommended, as
its absorption is dependent on administration
with a fatty meal and is highly variable in HSCT
recipients, especially those with acute GVHD.44
In a study that used oral posaconazole 200 mg 3
times/day for prophylaxis in patients with severe
GVHD, among patients for whom the results of
pharmacokinetic testing were available, the mean
concentration of posaconazole was 1.470 mg/L in
the 82 patients with chronic GVHD and 0.958
mg/L in the 158 patients with acute GVHD.44 In
the five patients who developed IFIs, median and
peak plasma concentrations were 611 and 635
ng/ml, respectively, versus 922 and 1360 ng/ml,
respectively, in the 241 patients without an IFI.
The small number of subjects in the group who
developed fungal infection precludes conclusions
regarding a therapeutic range for prophylaxis of
fungal infections, or the dosages of posaconazole
required to achieve this range.
Comparative Studies
Before oral systemic antifungal agents such as
fluconazole became available, clinicians used oral
nonabsorbable antifungals (e.g., amphotericin B,
nystatin, and clotrimazole) to prevent superficial
fungal infections like oral thrush or esophagitis.
These agents, however, were of little utility in
preventing systemic IFIs and therefore are not
discussed further except when they were used as
comparators in studies that assessed oral
absorbable azoles or intravenous antifungals.
Numerous studies have compared antifungal
agents with placebo, nonabsorbable antifungals,
or other systemic antifungals, for prophylaxis in
both autologous and allogeneic HSCT recipients.
In most studies, antifungal prophylaxis was begun
at the start of or within 72 hours of the start of
the conditioning regimen; however, the dosages
and formulations of the antifungal agents and the
durations of antifungal prophylaxis have been
inconsistent. In particular, various dosages and
formulations of fluconazole, itraconazole, and
amphotericin B have been evaluated. Prophylaxis
has been administered until engraftment (ANC >
500–1000 cells/mm3 for 2–7 consecutive days) or
until a predefined time point (~ 42–180 days)
after HSCT, the development of intolerable adverse
effects, or the occurrence of proven or probable
IFIs or death. Study end points generally include
the occurrence of proven IFIs, or the combined
occurrence of proven, probable, or possible IFIs,
although some studies include IFI-related
mortality, adverse effects, compliance, breakthrough
probable or proven IFIs, or initiation of anti-
fungal therapy for empiric or probable or proven
IFI. However, the definitions of proven,
probable, and possible infection differ among
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studies. Moreover, most studies were not
sufficiently powered to enable determination of
statistically significant differences between
groups for each of these end points. Despite
these limitations, the results of these studies have
shaped clinical practice. Table 2 provides the
descriptions and results, respectively, of the 26
trials we identified that evaluated various agents
for primary antifungal prophylaxis in HSCT
recipients, as discussed in the following
sections.2, 3, 36, 37, 45–66
Fluconazole
Fluconazole was the first oral systemic anti-
fungal agent to receive FDA approval for the
prophylaxis of candidiasis in patients under-
going HSCT. Fluconazole offers the advantage
of availability in both parenteral and oral
formulations with systemic activity against a
wide range of Candida species. Fluconazole was
compared with placebo or oral nonabsorbable
antifungals in seven randomized, comparative
trials.2, 3, 47–49, 52, 61 Despite differences in the
number of autologous and allogeneic HSCT
recipients, the duration of prophylaxis, and the
dosages of fluconazole used in each study,
significant decreases (8–14%) in proven IFIs
were demonstrated in five studies (one of which
included proven, probable, and possible IFIs) in
patients who received fluconazole prophylaxis. 2,
3, 47–49
Fewer IFI-related deaths were observed in the
three studies47–49 (among the five in which this
end point was assessed2, 47–49, 61) in which patients
received fluconazole 400 mg/day from the start of
conditioning until day 60–75 after transplan-
tation; however, only one of the five studies
demonstrated a significant decrease in mortality.
There was no benefit of fluconazole prophylaxis
on overall mortality in four of the five trials that
assessed this end point,2, 48, 49, 52 with the one
exception being the study47 in which the
fluconazole group had a 14.7% reduction in
overall mortality (p value not reported) and a
lower probability of death by day 110 (p=0.004).
A potential reason for the overall mortality
benefit observed in this study is that the patients
were predominantly higher risk allogeneic HSCT
recipients, compared with the other studies in
which a balanced number of autologous and
allogeneic HSCT recipients and/or patients with
hematologic malignancies were evaluated. In a
follow-up study 8 years later, a persistent survival
benefit due to fluconazole (44.7% and 27.7 % in
fluconazole- and placebo-treated patients,
respectively, p=0.0001) was observed, and
placebo treatment was independently associated
with a relative risk of death of 1.5 (95%
confidence interval 1.1–2).67 However, a major
limitation of the follow-up study was that the
investigators were unaware of whether the
patients had received fluconazole or other
antifungal agents after having participated in the
earlier trial.
Breakthrough IFIs with C. krusei, Aspergillus
species, and Zygomycetes have occurred in
patients receiving fluconazole prophylaxis.
Independent risk factors for failure of fluconazole
prophylaxis are older age, use of antibacterial
prophylaxis, use of cytarabine plus anthracycline–
based chemotherapy, and a high Candida
colonization index.49 Only one trial (discussed
above)47 commented on antifungal susceptibility
testing. Of six breakthrough C. glabrata isolates
that were resistant to fluconazole, two were
isolated from patients who had received
fluconazole prophylaxis, one of whom had been
colonized with fluconazole-susceptible C.
glabrata before beginning prophylaxis. A third
isolate was from a patient who received placebo
and had been colonized with fluconazole-
resistant C. glabrata before the study. Finally, a
Candida guilliermondii isolate from a patient who
had received fluconazole prophylaxis was
resistant to fluconazole.
In summary, fluconazole, at the dosages
evaluated, decreases the frequency of IFIs due to
Candida species, in particular C. albicans.
However, there is concern that lower doses of
fluconazole may not achieve adequate concen-
trations to exceed the minimum inhibitory
concentrations for the treatment of Candida
species such as C. glabrata, which typically
demonstrate higher minimum inhibitory
concentrations to azole antifungals than do C.
albicans.52 Fluconazole, at a dose of 400 mg/day,
decreases mortality due to IFIs in HSCT
recipients and has the additional benefit of
improving overall survival in allogeneic HSCT
recipients when a longer duration (to day 75
after transplantation) of prophylaxis is used,47
and an enduring benefit persists even after
discontinuation of fluconazole.67
Itraconazole
As fluconazole has no activity against Aspergillus
species or other moulds, itraconazole was
investigated as a prophylactic agent in the hopes
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Table 2. Description of Comparative Trials of Antifungal Agents
Patient Population Duration of Prophylaxis Study Groups
356 patients During conditioning and until day 70 Fluconazole 400 mg p.o. q.d. or 200 mg i.v.
Allogeneic BMT (n=171) after transplantation q12h
Autologous BMT (n=185)48 Mean: fluconazole 22.6 days, Placebo p.o. or i.v.
placebo 19.7 days
536 patients (511 evaluable) Before conditioning, until ANC Fluconazole 50 mg p.o. q.d.
HM (n=426) > 1000/mm3 or day 84 after Nystatin 4 x 106 U p.o. or amphotericin B
BMT (n=110)3 transplantation 2 g p.o. q.d.
90 patients Within 7 days of ANC < 1000/mm3, Fluconazole 200 mg p.o. q.d.
HM (n=67) until ANC > 1000/mm3 x 3 days Clotrimazole 10-mg troche q12h
BMT (n=23)2
300 patients During conditioning, until day 75 after Fluconazole 400 mg i.v. or p.o. q.d.
Allogeneic BMT (n=265) transplantation Placebo i.v. or p.o.
Autologous BMT (n=35)47
89 patients Not reported Fluconazole 400 mg i.v. or p.o. q.d.
HM (n=56) Nystatin 24 x 106 U t.i.d. p.o. + inhaled
Allogeneic BMT (n=30) miconazole t.i.d.
Autologous BMT (n=3)61
304 patients During conditioning, until day 60 after Fluconazole 400 mg p.o. q.d.
HM (n=184) transplantation Placebo p.o.
Autologous BMT (n=120)49
253 patients (early prophylaxis) During conditioning, until ANC Fluconazole 400 mg p.o. q.d.
Allogeneic BMT (n=142) ≥ 1000/mm3 x 3 days
Autologous BMT (n=111)52 Fluconazole 200 mg p.o. q.d.
172 patients Until ANC ≥ 1000/mm3 x 3 days or Fluconazole 100 mg p.o. q.d.
(maintenance prophylaxis) day 100 after transplantation Clotrimazole 10-mg troche q.i.d.
Allogeneic BMT (n=95)
Autologous BMT (n=77)52
405 patients Before conditioning, until ANC Itraconazole 2.5 mg/kg p.o. (solution) b.i.d.
HM (n=331) > 1000/mm3 or 56 days after
Autologous BMT (n=74)50 transplantation Placebo p.o.
445 patients During conditioning, until ANC Itraconazole 2.5 mg/kg p.o. (solution) b.i.d.
HM (n=215) ≥ 1000/mm3 x 7 days Fluconazole 100 mg p.o. (suspension) q.d.
Allogeneic BMT (n=51)
Autologous BMT (n=179)
202 patients During conditioning, until ANC Itraconazole 100 mg p.o. (capsule) b.i.d.
HM (n=87) > 500/mm3 Fluconazole 50 mg p.o. b.i.d.
Autologous HSCT (n=115)h, 62
210 patients During conditioning until ANC Itraconazole 100 mg p.o. (capsule) q12h
HM (n=179) > 1000/mm3 x 3 days Placebo p.o.
Autologous BMT (n=31)63
140 patients (138 evaluable) Days 1–100 after transplantation Itraconazole 200 mg i.v. q12h x 2 days,
Allogeneic HSCT (n=138)h, 36 then 200 mg i.v. q.d. x 12 days, then
200 mg p.o. (solution) q12h
Fluconazole 400 mg i.v. q.d. x 14 days,
then 400 mg p.o. q.d.
304 patients (299 evaluable) During conditioning, until a minimum Itraconazole 2.5 mg/kg p.o. (solution) t.i.d.
Allogeneic HSCT (n=299)h, 37 of 120 days (if GVHD, until 28 days or 200 mg i.v. q.d.
after steroid use or day 180 after Fluconazole 400 mg p.o. or i.v. q.d.
transplantation)
195 patients During conditioning, until resolution Itraconazole 200 mg p.o. (solution) b.i.d.
HM (n=43) of neutropenia or to a maximum of or 200 mg i.v. q.d.
Allogeneic HSCT (n=44)h 56 days after transplantation Fluconazole 400 mg p.o. or i.v. q.d.
Autologous HSCT (n=108)h, 45 (mean 17 days, both groups)
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Table 2. (continued)
IFI Rate, Mortality Rate, % (no.)
% (no.) Pathogens Causing IFIs (no.) Due to IFI Overall
2.8 (5) C. albicans + C. tropicalis (1), Candida sp (1), Aspergillus sp (1), Aspergillus sp + 0.6 (1) 30.7 (55)a
C. parapsilosis (1), Zygomycetes (1)
15.8 (28) C. krusei (3), Aspergillus sp (1), Zygomycetes (1), C. albicans (11), C. tropicalis (5), 5.6 (10) 26.0 (46)a
p<0.001 C. glabrata (2), C. lusitaniae (2), C. parapsilosis (1) p<0.001 p=0.38
3.9 (10) C. krusei (3), A. fumigatus (2), Acremonium sp (1) NA NA
12.2 (31) C. krusei (3), C. albicans (2), C. tropicalis (2), C. rugosa (1), Zygomycetes (1) NA NA
p=0.001
7.0 (3)b Aspergillus sp (1), Fusarium sp (1), clinically documented IFI (1) 4.9 (2)b 14.2 (6)
22.0 (11)b C. albicans + C. tropicalis (1), A. flavus (1), Aspergillus sp (3), Aspergillus sp + 18.8 (9)b 16.7 (8)
p<0.05 Alternaria sp (1), Aspergillus sp + C. krusei (1), Aspergillus sp + Fusarium sp (1), p<0.06 p=NS
Acremonium sp (1), clinically documented IFI (2), clinically documented IFI +
C. lusitaniae (1)
7.0 (10) C. glabrata (3), C. guilliermondii (1), A. fumigatus (3), Fusarium sp (1), unknown (2) 7.2 (11) 20.4 (31)c
18.0 (26) C. albicans (18), C. glabrata (6), C. tropicalis (2), C. parapsilosis (1), 12.8 (19) 35.1 (52)c
p<0.004 C. pseudotropicalis (1), yeast not specified (1), A. fumigatus (2), Fusarium sp (1) NA NA
2.3 (1) A. fumigatus (1) 2.3 (1) NA
4.3 (2) Candida sp (1), Aspergillus sp (1) 0 NA
p=NS NA
3.0 (4) C. albicans (1), C. krusei (1), Aspergillus sp + C. tropicalis (1) 0.7 (1) 9.8 (15)
17.0 (22) C. albicans (6), C. krusei (1), C. tropicalis (1), C. lusitaniae (1) 4.0 (6) 9.9 (15)
p=0.0003 p=0.04 NA
8.0 (9) C. albicans (1), C. tropicalis (2), C. glabrata (2), A. fumigatus (4), A. glaucus (1), NA 19.0 (24)
Aspergillus sp (1)d
2.0 (3) C. glabrata (1), A. flaxus (1), Aspergillus sp (1)d NA 16.0 (20)
p=0.06 NA
3.4 (3) C. krusei (1), A. fumigatus (2), A. fumigatus + A. nidulans (1)e NA 18.2 (16)
1.2 (1) NA 16.7 (14)
NA p=NS
2.5 (5) C. parapsilosis (1), A. fumigatus (1), A. flavus (1), Aspergillus sp (1), A. flavus + 0.5 (1) 7.0 (15)
Fusarium sp (1)
4.4 (9) C. albicans (3), C. tropicalis (3), C. parapsilosis (1), Trichosporon capitatum (1), 2.5 (5) 9.0 (18)
p>0.2 Aspergillus sp (1) p=0.11 NA
0.3 (1)f C. albicans (1) 0 (0)f 1.0 (3)f
2.0 (6)f C. tropicalis (1), C. krusei (1), Aspergillus sp (4) 1.4 (4)f 3.8 (11)f
p=NS NA NA
7.9 (8)g A. fumigatus (4), clinically documented IFI (4) 5.9 (6)g 10.9 (11)
11.0 (11)g A. fumigatus (2), Zygomycetes (2), clinically documented IFI (7) 3.0 (3)g 6.9 (7)
NA NA p=NS
4.8 (5) C. tropicalis (1), C. lusitaniae (1), Rhodotorula rubra (1), Exophiala jeanselmei (1) 1.9 (2) 7.7 (8)
8.5 (9) Candida sp (3), C. albicans (1), C. tropicalis (1), C. glabrata (1), A. fumigatus (1), 0.9 (1) 6.6 (7)
p=0.28 E. jeanselmei (1) NA p=0.76
9.0 (6)d C. glabrata + C. krusei (1), C. guilliermondii (1), Aspergillus sp (3), Zygomycetes (1) 9.0 (6) 45.0 (32)a
25.0 (17)d C. glabrata (4), C. krusei (3), C. tropicalis (1), Aspergillus sp (8), Fusarium sp (1) 18.0 (12) 42.0 (28)a
p=0.01 p=0.13 p>0.2
13.0 (20)b C. glabrata (2), C. parapsilosis (1), A. fumigatus (5), Aspergillus sp (2), A. niger + 8.0 (12) 23.8 (36)
Cunninghamella sp (1)
16.0 (25)b C. parapsilosis (2), C. glabrata (1), C. krusei (1), A. fumigatus (11), Aspergillus sp (2), 7.0 (11) 19.2 (29)
p=0.46 A. terreus (2), A. niger (1), A. fumigatus + A. niger (1) NR NR
11.0 (11)g C. glabrata (1), C. tropicalis (1), Aspergillus sp (9)l 5.2 (5)g 29.2 (28)
12.0 (12)g C. krusei (1), Aspergillus sp (11)l 9.1 (9)g 30.2 (30)
p=NS p=NS p=NS
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of preventing IFIs from these pathogens as well
as Candida species. However, the results of
studies evaluating itraconazole for prophylaxis
were difficult to evaluate, as several doses and
formulations of itraconazole have been compared
with a variety of agents. Similarly, a variety of
end points have been assessed: proven IFIs;
proven, probable, possible IFIs; proven IMIs and
candidemia; and microbiologically and clinically
documented IFIs.
Itraconazole prophylaxis in HSCT recipients
has been evaluated in seven randomized
studies.36, 37, 45, 50, 57, 62, 63 Overall, the studies
demonstrated no significant difference in IFI
rates between itraconazole and fluconazole or
placebo, with one exception.36 This open-label
trial of allogeneic HSCT recipients who received
fluconazole or intravenous itraconazole followed
by oral itraconazole solution, demonstrated a
significant difference in the rate of proven IFIs
(itraconazole 13% vs fluconazole 28%, p=0.03).36
Unfortunately, the small sample size prevented an
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Table 2. Description of Comparative Trials of Antifungal Agents (continued)
Patient Population Duration of Prophylaxis Study Groups
182 patients Not reported Amphotericin B 1 mg/kg i.v. q.d.
Autologous BMT (n=182)60 Placebo i.v.
76 patients Initiated when ANC < 500/mm3 x L-amphotericin B 1 mg/kg i.v. q.d.
Allogeneic BMT (n=63) 2 days, until ANC > 500/mm3 x 2 days Placebo i.v.
Autologous BMT (n=13)59 or day 90 after transplantation
35 patients Initiated when ANC ≤ 500/mm3,until Amphotericin B 1 mg/kg i.v. q.d.
Allogeneic BMT (n=24) ANC > 500/mm3 x 2 days Placebo i.v.
Autologous BMT (n=11)64
161 patients During conditioning, until ANC L-Amphotericin B 2 mg/kg i.v. 3x/wk
HM (n=26) > 500/mm3 x 3 days Placebo i.v.
Allogeneic BMT (n=85)
Autologous BMT (n=50)53
382 patients Initiated at randomization, until ANC Aerosolized amphotericin B 10 mg b.i.d.
HM (n=318) > 1000/mm3 x 2 days or day 50 after No aerosolized prophylaxis
Autologous BMT (n=64)58 transplantation
355 patients Initiated on day 1, until ANC > 500/mm3 Amphotericin B 0.2 mg/kg i.v. q.d.
Allogeneic HSCT (n=103)h (maximum 20 mg/day)
Autologous HSCT (n=252)h, 51 Fluconazole 400 mg i.v. or p.o. q.d.
186 patients Initiated on day before conditioning, Amphotericin B 0.2 mg/kg i.v. q.d.
Allogeneic HSCT (n=140)h until ANC > 500/mm3 x 3 days (maximum 10 mg/day)
Autologous HSCT (n=46)h, 56 Fluconazole 200 mg p.o. q.d.
217 patients Initiated 1–2 days before ANC L-amphotericin B 50 mg i.v. q.o.d.
HM (n=189) < 500/mm3, until ANC ≥ 500/mm3 No prophylaxis
Autologous HSCT (n=28)h, 54
271 patients Initiated at randomization, until ANC Aerosolized L-amphotericin B 12.5 mg q.d.
HM (n=185) > 300/mm3 or maximum of 12 x 2 consecutive days/wk
Allogeneic HSCT (n=30)h inhalations per neutropenic episode Placebo inhalation q.d. x 2 consecutive days/wk
Autologous HSCT (n=56)h, 66 Patients also received fluconazole prophylaxis
882 patients (880 evaluable) Before conditioning, until ANC Micafungin 50 mg i.v. q.d.
Allogeneic HSCT (n=476)h ≥ 500/mm3 or day 42 after
Autologous HSCT (n=404)h, 46 transplantation Fluconazole 400 mg i.v. q.d.
600 patients Fixed 112-day treatment period Posaconazole 200 mg p.o. (suspension) t.i.d.
Allogeneic HSCT (n=600)h, 55
Fluconazole 400 mg p.o. q.d.
600 patients Days 0–100 or until day 180p after Voriconazole 200 mg q12h p.o. or i.v.
Allogeneic HSCT (n=600)h, 65 transplantation Fluconazole 400 mg p.o. or i.v. q.d.
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Table 2. (continued)
IFI Rate, Mortality Rate, % (no.)
% (no.) Pathogens Causing IFIs (no.) Due to IFI Overall
6.6 (6)i Presumed IFI (2) NA 3.3 (3)
17.6 (16)i Candida sp (3), presumed IFI (2) NA 12.1 (11)
NA p<0.03
3 (1) C. guillermondi (1) 2.8 (1) 44.4 (16)
8 (3) C. albicans (1), C. guillermondii (2) 5 (2) 32.5 (13)
p=NS NA NA
12.0 (2) C. albicans (1), Aspergillus sp (1) NA 17.6 (3)j
28.0 (5) C. tropicals (1), Curvularia sp (1), Cladosporium sp (1), Coccidioides sp (1) NA 50.0 (9)j
p=0.4 p=0.097
0 (0) None 1.4 (1)k 15 (11)
2.3 (2) Candida sp (2) 1.1 (1)k 14 (12)
p=NS NA NA
4 (10)l IPA (10)k 1.3 (3)m 13.2 (30)
7 (11)l IPA (11)k 1.3 (2)m 9.7 (15)
p=0.37 NA NA
1.9 (3) C. albicans (8), C. glabrata (1), C. parapsilosis (2), Aspergillus sp (1) 1.3 (2) 11.9 (19)
2.6 (5) C. albicans (2), C. glabrata (2), C. parapsilosis (1), C. krusei (1), Aspergillus sp + 2.6 (5) 12.2. (24)
p>0.05 C. glabrata (1), Aspergillus sp + C. krusei (1) p>0.05 p>0.05
12.8 (11) C. albicans (2), C. parapsilosis (2), Candida sp (2), Aspergillus sp (2), others (3) 7 (6) 29.1 (25)
12.0 (12) C. parapsilosis (6), C. tropicalis (2), C. glabrata (1), C. krusei (1), Aspergillus sp (1), 6 (6) 22.0 (22)
NA other (1) NA NA
4.6 (5)n C. albicans (1), C. tropicalis (1), C. krusei (1), A. fumigatus (2) 1.8 (2) 3.7 (4)
20.2 (22)n C. albicans (2), C. glabrata (1), C. tropicalis (3), A. fumigatus (3) 7.3 (8) 8.2 (9)
p<0.01 p=0.07 p=0.13
4 (6)o IPAn (6) 3.6 (5) NA
14 (18)o IPAn (18), Fusarium sp (1) 4.5 (6) NA
p=0.005 p=0.8
1.6 (7)n C. albicans (1), C. glabrata (1), C. parapsilosis (1), C. lusitaniae (1), probable 0.2 (1) 4.2 (18)
aspergillosis (1), Zygomycetes (1), Fusarium sp (1)
2.4 (11)n C. parapsilosis (1), C. krusei (1), proven aspergillosis (4), probable aspergillosis (3), 0.4 (2) 5.7 (26)
p=0.481 Fusarium sp (2) NA p=0.322
5.3 (16)n C. glabrata (1), Trichosporon beigelii (1), probable IPA (3), Pseudallescheria 0.7 (2)n 19.3 (58)
boydii (1), mould not specified (1)
9.0 (27)n C. albicans (1), C. glabrata (1), C. krusei (1), A. fumigatus (6), A. flavus (2), A. terreus (1), 3.8 (11)n 19.7 (59)
p=0.07 Aspergillus sp (4), probable IPA (4), Zygomycetes (1), mould not specified (1) p=0.046 NA
11.6 (13)q Candida sp (3), Aspergillus sp (7), Zygomycetes (2), other (1) NA NA
13.1 (23)q Candida sp (3), Aspergillus sp (16), Zygomycetes (3), other (1) NA NA
p=0.5
IFI = invasive fungal infection; BMT = bone marrow transplant; ANC = absolute neutrophil count; HM = hematologic malignancy; NA = not
available; HSCT = hematopoietic stem cell transplant; GVHD = graft-versus-host disease; NR = not reported; L = liposomal; NS = not
statistically significant; IPA = invasive pulmonary aspergillosis.
aOverall mortality at 90 days after transplantation.
bProven, probable, and possible IFIs.
cOverall mortality at 110 days after transplantation.
dIFIs occurring within 50 days of BMT.
eDid not report in which maintenance group patients were enrolled.
fDocumented as “per episode” since some patients entered into the study more than once.
gMicrobiologically and clinically documented IFIs.
hIf not specified as BMT or peripheral blood stem cell transplant, included as HSCT, with autologous or allogeneic if specified.
iProven and suspected IFIs.
jOverall mortality at 1-yr follow-up.
kMortality from proven and possible IFIs.
lIncludes proven, probable, and possible IPA.
mMortality from proven and probable IPA.
nProven and probable invasive mould infections and candidemia.
oIncludes proven and probable IPA.
pProphylaxis was continued until day 180 after transplantation in patients who received prednisone ≥ 1 mg/kg/day or a T-cell–depleted HSCT.
qProven, probable, and presumptive IFI rate at 12 mo.
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adequate test of prophylaxis versus Aspergillus
species. The rate of IFIs in fluconazole-treated
patients was higher than that reported in
previous studies2, 3, 47–49, 52, 61 that evaluated
fluconazole prophylaxis, perhaps because the
fluconazole group included more patients with
matched unrelated donor HSCTs, acute GVHD
(grades II–IV), and chronic GVHD than in the
itraconazole group, potentially biasing this study
in favor of itraconazole.
In light of itraconazole’s additional mould
coverage, it was hoped that significant differences
would be seen in terms of IMIs. However, thus
far, the potential benefit has been demonstrated
only in high-risk patient populations. The two
studies that included only allogeneic HSCT recip-
ients36, 37 were able to demonstrate a significant
decrease in IFIs; however, only one of the studies37
was able to demonstrate a difference in IMIs (5%
vs 12% itraconazole vs fluconazole groups,
p=0.03), most likely because patients in the study
were at very high risk for IMIs. Approximately
half of the patients in each group had received
HSCTs with unmatched related donors or
matched unrelated donors, and about 80% of the
patients in each group had acute grades II–IV
GVHD. By contrast, in the five studies composed
mainly of patients with hematologic malignancies
or autologous HSCT recipients, no benefit was
demonstrated.45, 50, 57, 62, 63
A benefit in terms of deaths due to IFIs or
overall mortality was not observed in any of the
seven itraconazole prophylaxis trials. Furthermore,
in three studies, significantly more adverse effects
(especially gastrointestinal complaints),
laboratory abnormalities, and withdrawals due to
adverse effects were noted in the itraconazole
than in the fluconazole group.36, 37, 57 In each of
these studies, oral itraconazole solution was used;
mean itraconazole concentrations (which were
not measured in all patients) were greater than
0.5 µg/ml. In addition, patients receiving concur-
rent cyclophosphamide therapy with itraconazole
exposes patients to higher concentrations of
acrolein (a toxic metabolite of cyclophosphamide)
compared with patients receiving fluconazole.37, 68
Breakthrough IFIs with both itraconazole-sus-
ceptible (Aspergillus species) and itraconazole-
resistant (C. krusei, C. tropicalis, and C. glabrata)
isolates have occurred in patients receiving
itraconazole prophylaxis.
As there is conflicting evidence about the
utility of itraconazole for prophylaxis, clinicians
must make the decision to use this agent based
on each individual patient’s risk for IMIs. The
benefit of using a mould-active agent was seen in
two studies,36, 37 one of which showed a benefit in
terms of IFIs and one in terms of IMIs. Both of
these studies included allogeneic HSCT
recipients, and some patients had received
unmatched related donor or matched unrelated
donor HSCTs and had evidence of GVHD—all
factors that increase the risk for IMIs. Thus,
allogeneic HSCT recipients should receive
prophylaxis with mould-active agents in the
presence of other risk factors for IMIs such as
unmatched related donor or matched unrelated
donor HSCTs, GVHD, and immunosuppressive
therapy. Perhaps the most important issue that
would need to be addressed with the patient is
adherence to the agent, as there are significantly
more adverse effects with itraconazole than with
fluconazole.
Amphotericin B
Amphotericin B has been investigated as a
prophylactic agent in nine studies, primarily
because of its broad-spectrum activity against
Candida species, Aspergillus species, and
Zygomycetes.51, 53, 54, 56, 58–60, 64, 66 Varying doses,
dosing schedules (every day or every other day),
formulations (conventional, lipid), and routes of
administration (oral, intravenous, aerosolized)
have been evaluated. In all but two studies,51, 56
amphotericin B was compared with placebo or no
prophylaxis. In only one study,54 however, was a
decrease in the rate of IFIs observed; similarly,
only one study60 demonstrated a significant
benefit in overall mortality.
Despite the use of higher intravenous doses of
amphotericin B 0.2 mg/kg/day than had been
used in trials comparing it with placebo, studies
comparing conventional amphotericin B with
fluconazole 200 or 400 mg/day failed to
demonstrate a difference in rates of IFIs,
mortality due to IFIs, or overall mortality.51, 56
However, this dose is considerably lower than
that recommended for treatment, which may
have contributed to its inability to demonstrate
impressive efficacy. Furthermore, patients in the
amphotericin B groups experienced increased
rates of renal toxicity compared with those in the
fluconazole groups.
Finally, the use of inhaled amphotericin B has
been studied for prophylaxis in order to limit the
systemic toxicities of the drug. Aerosolized
conventional amphotericin B provided no benefit
over no aerosolized prophylaxis in terms of the
cumulative incidence of proven, probable, or
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possible invasive pulmonary aspergillosis.58 In
contrast, prophylaxis with inhaled liposomal
amphotericin B decreased the frequency of
invasive pulmonary aspergillosis compared with
placebo (all patients also received fluconazole
prophylaxis).66 Differences in efficacy between
formulations may be a result of the aerosol
delivery systems used, their pulmonary
pharmacokinetics, or that the liposomal carrier
exhibits a pulmonary surfactant-like function
whereas the deoxycholate formulation impairs
surfactant function. However, the technical
aspects of the administration and adverse effects
of inhaled amphotericin B have yet to be refined.
Thirty-one percent of patients discontinued the
inhaled conventional amphotericin B, with 55%
discontinuing due to adverse effects (cough,
nausea, dizziness, tightness in the chest), 30%
due to the inability to cooperate, and 4% because
of noncompliance.58 Also, more patients
discontinued the inhaled liposomal amphotericin
B than placebo (45% vs 30%, p=0.01) because
they either could not use the nebulizer properly,
had technical problems, or experienced coughing
during inhalation.66
Breakthrough IFIs that occurred in the
amphotericin B prophylaxis trials are listed in
Table 2. None of the studies evaluated suscep-
tibilities to amphotericin B or comparators. The
increased risk of toxicity with conventional
amphotericin B, high cost of liposomal
amphotericin B, and equivocal results from trials
preclude its routine use as a prophylactic strategy,
and more studies are needed to access the
efficacy of aerosolized amphotericin B for
prophylaxis.
Micafungin
Despite their availability in only intravenous
formulations, the echinocandins are of interest
for prophylaxis (especially for patients who are
intolerant of or allergic to azoles or who are
receiving coadministration of immunosuppres-
sive agents) because they display fewer drug
interactions (compared with the azoles) and they
are generally well tolerated. In addition, they
have a broad spectrum of activity, which includes
Candida and Aspergillus species (but not
Zygomycetes or Cryptococcus neoformans).
However, to our knowledge, micafungin is the
only echinocandin that has been studied in a
randomized controlled trial for prophylaxis in
adult HSCT recipients.46
In this study, autologous and allogeneic HSCT
recipients were randomly assigned to prophylaxis
with either intravenous micafungin 50 mg/day or
intravenous fluconazole 400 mg/day.46 Micafungin
was superior in terms of treatment success
(defined as the composite end point of absence of
a proven, probable, or suspected IFI at the end of
prophylaxis and the absence of proven or
probable IFI at the end of the 4-week post-
prophylaxis period) compared with fluconazole
(80% micafungin, 73.5% fluconazole, p=0.03).
However, the rates of proven and probable IFIs,
breakthrough aspergillosis, breakthrough
candidiasis, adverse effects, discontinuation due
to adverse effects, deaths due to IFIs, and overall
mortality were similar between groups. Antifungal
susceptibilities were not evaluated in this trial.
Thus, this study validated that micafungin was as
effective as fluconazole as a prophylactic agent in
HSCT recipients and can be used as an alternative
in azole-intolerant patients. However, a major
limitation of this study was the relatively short
duration of prophylaxis, which did not allow
assessment of the efficacy of micafungin for
prophylaxis in the postengraftment and late-
phase high-risk periods for infections.
Voriconazole and Posaconazole
The recent availability of extended-spectrum
azole antifungal agents, such as voriconazole and
posaconazole, has led clinicians to inquire
whether these agents may be superior prophy-
lactic agents compared with fluconazole or
itraconazole in HSCT recipients. Voriconazole
has activity against Candida and Aspergillus
species and is available orally and intravenously.
Posaconazole has a similar spectrum of activity
that also includes the Zygomycetes; however, it is
only available orally.
Voriconazole was studied for prophylaxis in
allogeneic HSCT recipients.65 On day 0 (day of
transplantation), patients were randomly
assigned to receive either voriconazole or
fluconazole intravenously or orally up to day
100, or day 180 if they received a T-cell–depleted
HSCT or were receiving 1 mg/kg/day or more of
prednisone. The study, which was powered to
detect a 10% difference in fungal-free survival
(freedom from proven or probable IFI or death at
6 mo), found no significant difference in fungal-
free survival or in the cumulative rates of proven,
probable, and presumptive IFIs or in overall
mortality. Although the difference was not
statistically significant, fewer patients in the
voriconazole group developed microbiologically
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documented infections due to Aspergillus species
(voriconazole 7 vs fluconazole 16, p=0.05).
These preliminary results, available only in
abstract form, suggest that voriconazole provides
no benefit over fluconazole in allogeneic HSCT
recipients.
Posaconazole was compared with fluconazole
in allogeneic HSCT recipients (at any time after
HSCT) with acute grades II–IV GVHD or chronic
GVHD while receiving immunosuppressive
regimens.55 Patients were randomly assigned to
receive one of the azoles orally for a fixed
treatment period of 112 days. Posaconazole was
noninferior (and not superior) to fluconazole in
terms of the primary end point, which was the
frequency of proven or probable IFIs at the end
of the 112-day treatment period, in the intent-to-
treat population (fluconazole 9%, posaconazole
5.3%, p=0.07). However, at the end of the 112-
day treatment period, posaconazole recipients
had fewer IFIs due to Aspergillus species
(fluconazole 7%, posaconazole 2.3%, p=0.006).
Further, posaconazole recipients had fewer total
breakthrough IFIs during the exposure period
(day of first study drug dose until 7 days after
receipt of the last study drug dose; fluconazole
8%, posaconazole 2%, p=0.004) and fewer
breakthrough IFIs due to Aspergillus species
during the exposure period (fluconazole 6%,
posaconazole 1%, p=0.001). Fewer deaths due to
proven or probable IFIs occurred in the
posaconazole group, although there was no
significant difference in overall mortality between
the groups.
This study is a good example of targeting
prophylaxis to a very specific group of patients at
high risk for IFIs. Although posaconazole was
not superior to fluconazole for the primary end
point, it was shown to be noninferior to
fluconazole and did decrease the number of
deaths due to IFIs. It is important to note that
the study did not address when mould prophy-
laxis should be started after transplantation.
Although randomization occurred at various time
points after transplantation, most patients were
randomized more than 101 or between 30 and 60
days after transplantation and many patients had
received fluconazole for antifungal prophylaxis
before entering into the study. As the benefit of
posaconazole prophylaxis has only been seen in a
very specific subgroup of HSCT recipients who
should be considered very high risk patients,
potential patients should be evaluated for their
risk factors for IFIs, ability to take oral drugs,
ability to eat a fatty meal, and potential for drug-
drug interactions before starting posaconazole
prophylaxis.
A limitation to the above posaconazole and
voriconazole studies is that the comparator,
fluconazole, does not have any mould coverage.
Two studies comparing voriconazole with
itraconazole in allogeneic HSCT recipients will
address this issue.69, 70 Preliminary results from
the first study, which evaluated open-label
primary prophylaxis with either voriconazole or
itraconazole for up to 180 days after transplan-
tation, found that prophylactic success was
significantly higher with voriconazole than with
itraconazole at 100 and 180 days, but there was
no significant difference in survival at 180 days.69
Unfortunately, as intravenous itraconazole is no
longer commercially available, the results of these
studies will be applicable only for patients able to
tolerate oral formulations of itraconazole. Another
key issue not addressed in the aforementioned
studies that needs to be addressed in future
studies is the monitoring of voriconazole and
posaconazole concentrations, as the oral bioavail-
ability of these agents can be erratic. Wide
interpatient variability in concentrations of
gastrointestinal CYP enzymes, drug-drug and
drug-disease interactions, and (for voriconazole)
the presence of genetic polymorphisms in
CYP2C19, contribute to the wide variability in
plasma concentrations observed for these
agents.33, 34, 39, 41, 42, 44
Cost-effectiveness studies in this population
are limited; however, a recent study concluded
that posaconazole is a cost-effective strategy for
the prevention of IFIs in patients with GVHD,
with an estimated incremental cost-effectiveness
(vs fluconazole) of $15,700/life-year saved, and
an 88% probability at a $50,000/life-year saved
threshold.71
Conclusion
It is important to target antifungal prophylaxis
by type of HSCT (autologous or allogeneic), local
epidemiology, and risk factors for IFIs so that
patients can receive the most appropriate agent
while balancing costs and the risks of toxicity,
and minimizing the development of resistance.
Based on the literature reviewed, fluconazole still
remains the gold standard for prophylaxis in
autologous and most allogeneic HSCT recipients
during the pre- and postengraftment period.
Itraconazole and micafungin are alternative
agents that may also be used in this population.
The subgroup of allogeneic HSCT recipients with
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severe GVHD benefit from the expanded mould
coverage of posaconazole. However, the optimal
times to begin and discontinue mould prophy-
laxis in this subgroup remain unknown. Despite
numerous studies, the question of whether
antifungal prophylaxis decreases mortality (either
all-cause or due to IFIs) has yet to be definitively
proven, and the optimal duration of antifungal
prophylaxis needs to be determined. It is unclear
whether Candida coverage with fluconazole
should be administered during the pre- and
postengraftment periods, followed by mould
coverage during the late phase in high-risk
patients, versus beginning administration of
mould-active therapy in the preengraftment
period and continuing it through the late phase.
The potential benefits of antifungal prophylaxis
depend on the basal rate of fungal infections; if
there is a very low rate of Aspergillus infections in
an institution, prophylaxis with mould-active
agents is likely not warranted.
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